NOK 1.9
(-5.0%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | -77.55 Million NOK | 45.41% |
2022 | -142.06 Million NOK | 36.9% |
2021 | -225.12 Million NOK | -7476.92% |
2020 | -2.97 Million NOK | 81.72% |
2019 | -16.25 Million NOK | -239.0% |
2018 | 11.69 Million NOK | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 Q3 | - NOK | 100.0% |
2023 Q1 | -130.6 Million NOK | 8.07% |
2023 Q4 | -72.89 Million NOK | 0.0% |
2023 FY | -77.55 Million NOK | 45.41% |
2023 Q2 | -109.61 Million NOK | 16.07% |
2022 FY | -142.06 Million NOK | 36.9% |
2022 Q4 | -142.06 Million NOK | 0.0% |
2022 Q2 | -177.76 Million NOK | 0.0% |
2021 Q2 | -242.4 Million NOK | 0.0% |
2021 FY | -225.12 Million NOK | -7476.92% |
2021 Q4 | -225.12 Million NOK | 0.0% |
2020 FY | -2.97 Million NOK | 81.72% |
2020 Q4 | -2.97 Million NOK | 0.0% |
2019 FY | -16.25 Million NOK | -239.0% |
2018 FY | 11.69 Million NOK | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
Aqua Bio Technology ASA | -5.82 Million NOK | -1230.526% |
ArcticZymes Technologies ASA | -237.27 Million NOK | 67.315% |
BerGenBio ASA | -155.55 Million NOK | 50.143% |
Hofseth BioCare ASA | 112.89 Million NOK | 168.693% |
PCI Biotech Holding ASA | -40.86 Million NOK | -89.784% |
Thor Medical ASA | -41.28 Million NOK | -87.853% |
Ultimovacs ASA | -262.84 Million NOK | 70.495% |